TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Understanding the Prognostic Benefits of Exercise and Anti-depressant Therapy (UPBEAT)
Brief Summary: Some individuals with coronary heart disease (CHD) suffer from depression and use antidepressant medications to reduce symptoms. However, preliminary research has shown that exercise may be a more effective way to treat depression in these individuals. The purpose of this study is to evaluate the effects of exercise in reducing depression and improving heart function in individuals with CHD.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Supervised Aerobic Exercise | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Pill. | Intervention Type: BEHAVIORAL; Name: Supervised Aerobic Exercise; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo Pill.; Assigned to Arm(s): 3
B: Arm Label: Internet-based CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based CBT | Arm Label: Treatment as usual (TAU); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Internet-based CBT; Assigned to Arm(s): Internet-based CBT
C: Arm Label: Escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: Placebo pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): Escitalopram | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo pill
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Home-based Metacognitive Therapy (Home-MCT) | Intervention Type: OTHER; Name: Home-based Metacognitive Therapy (Home-MCT); Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Placebo-Controlled Study of Mirtazapine for PTSD in OIF/OEF Veterans
Brief Summary: Objective: To study the efficacy and tolerability of mirtazapine (Remeron) in the treatment of PTSD.

Research Design: This is an 8-week randomized, double-blind, placebo-controlled treatment trial of mirtazapine for the treatment of PTSD as defined on the Clinical Assessment of PTSD Scale (CAPS).

Methodology: After signing an informed consent and meeting all inclusion/exclusion criteria, the patient is randomized to either mirtazapine versus placebo for 8-week duration. During the study a pharmacist maintains the randomization log and verifies the order for the placebo or mirtazapine in look-a-like tablets. Patients' symptoms, side effects and compliance are assessed bi-weekly. Based on symptomology and occurrence of side effects, the investigator increases the medication in 15 mg increments, as tolerated, until a maximum therapeutic benefit is achieved, not to exceed 45 mg/day. The dosing is at bedtime. Compliance is assessed by bi-weekly pill count at week 4 and week 8. Patients are given supportive clinical management during the clinic visits. An investigator is available by telephone 24 hrs a day in case of emergency. Patients may be seen more often if needed. Efficacy will be measured by the following assessment scales: Montgomery-Asberg Depression Rating Scale (MADRS), Hamilton Anxiety Scale (Ham-A), Clinical Global Impression Severity of Illness (CGI-s), Clinical Global Impression of Improvement (CGI-I), Global Assessment of Functioning (GAF), CAPS, Treatment Outcome PTSD rating scale (TOP-8), and Davidson Trauma Scale (DTS).

Clinical Significance: Mirtazapine has shown promise in treating PTSD in an open label trial. This study is the next step in proving mirtazapine's efficacy in treatment of PTSD.


Options:
A: Arm Label: Ketamine; Type: EXPERIMENTAL; Interventions: Drug: Ketamine | Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): Midazolam | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine
B: Arm Label: Eszopiclone; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Eszopiclone | Intervention Type: DRUG; Name: Eszopiclone; Assigned to Arm(s): Eszopiclone, Placebo
C: Arm Label: Treatment (Viibryd); Type: EXPERIMENTAL; Interventions: Drug: Treatment (Viibryd) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Treatment (Viibryd) | Intervention Type: DRUG; Name: Treatment (Viibryd); Assigned to Arm(s): Placebo, Treatment (Viibryd)
D: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mirtazapine | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mirtazapine; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Clinical Trial of Prognostic Factors and Surgical Methods for the Treatment of Idiopathic Macular Holes
Brief Summary: The project is a randomized clinical trial with a follow up time of 12 months comparing the effects of surgical treatment of idiopathic macular holes. Patients are randomized to vitrectomy alone, vitrectomy plus indocyanine green (ICG) assisted inner limiting membrane ( ILM) peeling or vitrectomy plus trypan blue (tb) assisted ILM peeling. At baseline patients are characterized using early treatment diabetic retinopathy study (ETDRS) visual charts, tests of aniseikonia, optical coherence tomography 3 (OCT3), visual field and fundus photography. Per- and postoperative complications are registered.

Data analyses will help clarify the effect of ILM peeling on hole closure and visual acuity. Comparing results after ICG- and tb assisted ILM peeling will help clarify the topic of a toxic effect on retinal cells after staining and peeling of the ILM. Changes in intraretinal morphology before and after dye-assisted ILM peeling will be studied using OCT3 imaging and the patients' subjective opinion on the surgical results will be analyzed using quality of life questionnaires and metamorphopsia tests.


Options:
A: Arm Label: Ocriplasmin 125µg; Type: EXPERIMENTAL; Interventions: Drug: Ocriplasmin 125µg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ocriplasmin 125µg; Assigned to Arm(s): Ocriplasmin 125µg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: macular hole operation no peeling; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Macular hole operation ICG peeling; Type: ACTIVE_COMPARATOR; Interventions: Procedure: macular hole operation | Arm Label: Macular hole operation TB peeling; Type: EXPERIMENTAL; Interventions: Procedure: macular hole operation | Intervention Type: PROCEDURE; Name: macular hole operation; Assigned to Arm(s): Macular hole operation ICG peeling, Macular hole operation TB peeling
C: Arm Label: ILM peeling; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Vitrectomy, post hyaloid detachment and gas injection with or without ILM peel. | Arm Label: No ILM peeling; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Vitrectomy, post hyaloid detachment and gas injection with or without ILM peel. | Intervention Type: PROCEDURE; Name: Vitrectomy, post hyaloid detachment and gas injection with or without ILM peel.; Assigned to Arm(s): ILM peeling, No ILM peeling
D: Arm Label: 125µg Ocriplasmin; Type: EXPERIMENTAL; Interventions: Drug: 125 µg Ocriplasmin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 125 µg Ocriplasmin; Assigned to Arm(s): 125µg Ocriplasmin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Step'n Out: A Multisite Trial of Collaborative Behavioral Management for Drug-Involved Parolees
Brief Summary: The main purpose of this study is to examine whether improved integration between the community supervision system and outpatient addiction treatment system can improve treatment adherence, drug use and public safety outcomes among drug-involved inmates re-entering the community.


Options:
A: Arm Label: COPE/Healthy Lifestyles TEEN Program; Type: EXPERIMENTAL; Interventions: Behavioral: COPE/Healthy Lifestyles TEEN Program. | Arm Label: Healthy Teens Attention Control Program; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Healthy Teens Attention Control Program | Intervention Type: BEHAVIORAL; Name: COPE/Healthy Lifestyles TEEN Program.; Assigned to Arm(s): COPE/Healthy Lifestyles TEEN Program | Intervention Type: BEHAVIORAL; Name: Healthy Teens Attention Control Program; Assigned to Arm(s): Healthy Teens Attention Control Program
B: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home visitation through pregnancy; Type: EXPERIMENTAL; Interventions: Behavioral: nurse home visitation | Arm Label: Home visitation through age 2; Type: EXPERIMENTAL; Interventions: Behavioral: nurse home visitation | Intervention Type: BEHAVIORAL; Name: nurse home visitation; Assigned to Arm(s): Home visitation through age 2, Home visitation through pregnancy
C: Arm Label: Information only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Information only | Arm Label: sexual risk reduction intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Sexual risk reduction intervention | Arm Label: SRRI+ETOH; Type: EXPERIMENTAL; Interventions: Behavioral: sexual risk reduction + alcohol risk reduction component | Intervention Type: BEHAVIORAL; Name: Information only; Assigned to Arm(s): Information only | Intervention Type: BEHAVIORAL; Name: Sexual risk reduction intervention; Assigned to Arm(s): sexual risk reduction intervention | Intervention Type: BEHAVIORAL; Name: sexual risk reduction + alcohol risk reduction component; Assigned to Arm(s): SRRI+ETOH
D: Intervention Type: BEHAVIORAL; Name: Collaborative Behavioral Management; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Integrated parole and outpatient addiction treatment; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of Multi-Source Feedback to Pediatric Residents: The Formative Value of an ACGME Competency-Based Assessment Tool.
Brief Summary: The purpose of this study is to test whether multi-source feedback, including self-assessment and tailored coaching, improves resident communication skills and professionalism. We hypothesize that residents who are assigned to receive multi-source feedback, in addition to receiving standard feedback, will improve significantly more than residents receiving standard feedback alone, as measured by parent and nurse ratings of specific behaviors over time.


Options:
A: Intervention Type: BEHAVIORAL; Name: Disease Management Assessment; Assigned to Arm(s): N/A
B: Arm Label: Transition Coordinator; Type: OTHER; Interventions: Other: Transition Coordinator | Arm Label: Current Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Transition Coordinator; Assigned to Arm(s): Transition Coordinator
C: Arm Label: lifestyle counseling tailored; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored counseling | Arm Label: lifestyle counseling motivational; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interview | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Tailored counseling; Assigned to Arm(s): lifestyle counseling tailored | Intervention Type: BEHAVIORAL; Name: Motivational Interview; Assigned to Arm(s): lifestyle counseling motivational
D: Intervention Type: BEHAVIORAL; Name: Multi-Source Feedback: including self-assessment & coaching; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of Multi-Source Feedback to Pediatric Residents: The Formative Value of an ACGME Competency-Based Assessment Tool.
Brief Summary: The purpose of this study is to test whether multi-source feedback, including self-assessment and tailored coaching, improves resident communication skills and professionalism. We hypothesize that residents who are assigned to receive multi-source feedback, in addition to receiving standard feedback, will improve significantly more than residents receiving standard feedback alone, as measured by parent and nurse ratings of specific behaviors over time.


Options:
A: Intervention Type: BEHAVIORAL; Name: Multi-Source Feedback: including self-assessment & coaching; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Educational intervention; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Educational intervention program; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: safety program; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Opinion Leaders, Academic Detailing, Reminders, and Feedback; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of Multi-Source Feedback to Pediatric Residents: The Formative Value of an ACGME Competency-Based Assessment Tool.
Brief Summary: The purpose of this study is to test whether multi-source feedback, including self-assessment and tailored coaching, improves resident communication skills and professionalism. We hypothesize that residents who are assigned to receive multi-source feedback, in addition to receiving standard feedback, will improve significantly more than residents receiving standard feedback alone, as measured by parent and nurse ratings of specific behaviors over time.


Options:
A: Intervention Type: BEHAVIORAL; Name: Multi-Source Feedback: including self-assessment & coaching; Assigned to Arm(s): N/A
B: Intervention Type: PROCEDURE; Name: Quality Initiative in Rectal Cancer (QIRC) strategy; Assigned to Arm(s): N/A
C: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Barrier assessment / interactive educational intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Barrier assessment / interactive educational intervention; Assigned to Arm(s): Intervention
D: Arm Label: Educational intervention; Type: EXPERIMENTAL; Interventions: Other: Educational intervention | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Educational intervention; Assigned to Arm(s): Educational intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combination Treatment With Bosentan and Sildenafil to Patients With Eisenmengers Syndrome
Brief Summary: The purpose of this study is to investigate if combination treatment with Bosentan and Sildenafil to patients with Eisenmenger syndrome is beneficial.


Options:
A: Arm Label: Inhaled treprostinil; Type: EXPERIMENTAL; Interventions: Drug: Inhaled treprostinil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo inhalation solution | Intervention Type: DRUG; Name: Inhaled treprostinil; Assigned to Arm(s): Inhaled treprostinil | Intervention Type: DRUG; Name: Placebo inhalation solution; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: bosentan | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Bosentan and Sildenafil; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Ambrisentan; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combination Treatment With Bosentan and Sildenafil to Patients With Eisenmengers Syndrome
Brief Summary: The purpose of this study is to investigate if combination treatment with Bosentan and Sildenafil to patients with Eisenmenger syndrome is beneficial.


Options:
A: Intervention Type: DRUG; Name: Bosentan and Sildenafil; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil citrate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sildenafil citrate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Arm 1
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Tadalafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tadalafil | Intervention Type: DRUG; Name: Tadalafil; Assigned to Arm(s): Tadalafil | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combination Treatment With Bosentan and Sildenafil to Patients With Eisenmengers Syndrome
Brief Summary: The purpose of this study is to investigate if combination treatment with Bosentan and Sildenafil to patients with Eisenmenger syndrome is beneficial.


Options:
A: Arm Label: Ambrisentan; Type: EXPERIMENTAL; Interventions: Drug: Ambrisentan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ambrisentan; Assigned to Arm(s): Ambrisentan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Bosentan for 16 weeks; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bosentan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): Bosentan for 16 weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): Bosentan for 16 weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Investigational treatment; Type: EXPERIMENTAL; Interventions: Drug: Macitentan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Macitentan; Assigned to Arm(s): Investigational treatment | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Bosentan and Sildenafil; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Trial for the Prevention of Premature Birth and Neonatal Related Morbidity
Brief Summary: The trial intends to evaluate the efficacy of specially designed probiotics to prevent premature birth and related neonatal morbidity associated to intra-uterine infection. The tested probiotics are efficacious to decrease the prevalence of bacterial vaginosis. The study hypothesis is that the early administration of those probiotics to pregnant women with bacterial vaginosis can prevent premature birth through antibiotic activity and modulation of the immune response to infection.


Options:
A: Intervention Type: DRUG; Name: Lactobacillus rhamnosus GR1 and Lactobacillus reuteri RC-14; Assigned to Arm(s): N/A
B: Arm Label: VSL#3 probiotic preparation; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: VSL#3 probiotic preparation | Arm Label: Placebo VSL#3; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo VSL#3 | Intervention Type: DIETARY_SUPPLEMENT; Name: VSL#3 probiotic preparation; Assigned to Arm(s): VSL#3 probiotic preparation | Intervention Type: OTHER; Name: Placebo VSL#3; Assigned to Arm(s): Placebo VSL#3
C: Arm Label: probiotics & allergy; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus rhamnosus GG | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus rhamnosus GG; Assigned to Arm(s): probiotics & allergy
D: Arm Label: Probiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotics | Arm Label: Probiotics + Dietary counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and probiotics | Arm Label: Dietary counseling + placebo; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and placebo | Arm Label: Prebiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Prebiotics | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo capsules | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary counselling and placebo; Assigned to Arm(s): Dietary counseling + placebo | Intervention Type: BEHAVIORAL; Name: Dietary counselling and probiotics; Assigned to Arm(s): Probiotics + Dietary counseling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo capsules; Assigned to Arm(s): Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Prebiotics; Assigned to Arm(s): Prebiotics

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study of Telemonitoring to Improve Heart Failure Outcomes
Brief Summary: The primary purpose of this study is to determine the effectiveness of telemonitoring compared with usual guideline-based care in preventing hospitalization for heart failure patients.


Options:
A: Arm Label: UC; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: TM; Type: EXPERIMENTAL; Interventions: Other: Telemonitoring | Intervention Type: OTHER; Name: Telemonitoring; Assigned to Arm(s): TM
B: Arm Label: Arm 1: PE via telemedicine; Type: EXPERIMENTAL; Interventions: Behavioral: Telemedicine | Arm Label: Arm 2: PE in person; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: In Person | Intervention Type: BEHAVIORAL; Name: Telemedicine; Assigned to Arm(s): Arm 1: PE via telemedicine | Intervention Type: BEHAVIORAL; Name: In Person; Assigned to Arm(s): Arm 2: PE in person
C: Arm Label: In-patient care; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual care | Arm Label: Telemedicine care; Type: EXPERIMENTAL; Interventions: Other: Telemedicine | Intervention Type: OTHER; Name: Telemedicine; Assigned to Arm(s): Telemedicine care | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): In-patient care
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: antipsychotic dose increase | Arm Label: TAU; Type: PLACEBO_COMPARATOR; Interventions: Other: no intervention | Intervention Type: DRUG; Name: antipsychotic dose increase; Assigned to Arm(s): A | Intervention Type: OTHER; Name: no intervention; Assigned to Arm(s): TAU

Answer: A